Pancrelipase - Johnson & Johnson

Drug Profile

Pancrelipase - Johnson & Johnson

Alternative Names: Pancreaze

Latest Information Update: 06 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ortho-McNeil-Janssen Pharmaceuticals
  • Developer Janssen Research & Development
  • Class Pancreatic enzymes
  • Mechanism of Action Pancrelipase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Exocrine pancreatic insufficiency

Most Recent Events

  • 04 Sep 2013 Janssen Research and Development, Aptalis Pharma and AbbVie initiate a porcine-virus safety trial in Cystic Fibrosis (NCT01858519)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top